Kozasa Katsumi, Mabuchi Seiji, Komura Naoko, Yokoi Eriko, Hiromasa Kuroda, Sasano Tomoyuki, Kawano Mahiru, Matsumoto Yuri, Kobayashi Eiji, Kimura Tadashi
Departments of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Oncotarget. 2017 Jul 25;8(33):55394-55404. doi: 10.18632/oncotarget.19560. eCollection 2017 Aug 15.
To compare the clinical utilities of the platelet count and platelet-lymphocyte ratio (PLR) for predicting survival in patients with cervical cancer.
Multivariate analyses demonstrated that thrombocytosis and elevated PLR were found to be independent prognostic factors for progression-free survival (PFS, = 0.0077, = 0.044) and overall survival (OS, = 0.025, = 0.019) in separate Multivariate analyses. In the ROC analysis, the platelet count showed a significantly greater area under the ROC curve (AUC) value than that of PLR for predicting patient recurrence (0.5941 versus 0.5331, = 0.018) and survival (0.6139 versus 0.5468, = 0.029). In patients without thrombocytosis, elevated PLR correlated with shorter survival (PFS, = 0.041; OS, = 0.017). In contrast, PLR in patients with thrombocytosis did not provide prognostic information. We divided patients into 3 prognostic groups using platelet counts and PLR: high-risk (thrombocytosis with any PLR); intermediate-risk (elevated PLR without thrombocytosis); low-risk (none of the above), which allowed for individualized and accurate survival estimates.
The baseline characteristics and clinical outcomes of cervical cancer patients were identified. Patients were grouped according to their pretreatment platelet counts or PLR, and clinicopathological characteristics and patient survival were then compared between these groups. The clinical utilities of the platelet count and PLR were compared using a time-dependent receiver operating characteristic (ROC) analysis.
Pretreatment thrombocytosis and elevated PLR were identified as independent predictors in cervical cancer patients. Platelet counts were superior to PLR for predicting the prognosis of uterine cervical cancer patients. Our prognostic model consisting of platelet counts and PLR offers individualized survival estimates.
比较血小板计数和血小板-淋巴细胞比值（PLR）预测宫颈癌患者生存的临床效用。
多因素分析表明，在单独的多因素分析中，血小板增多症和升高的PLR被发现是无进展生存期（PFS，P = 0.0077，P = 0.044）和总生存期（OS，P = 0.025，P = 0.019）的独立预后因素。在ROC分析中，血小板计数在预测患者复发（0.5941对0.5331，P = 0.018）和生存（0.6139对0.5468，P = 0.029）方面显示出比PLR显著更大的ROC曲线下面积（AUC）值。在无血小板增多症的患者中，升高的PLR与较短的生存期相关（PFS，P = 0.041；OS，P = 0.017）。相反，血小板增多症患者的PLR未提供预后信息。我们使用血小板计数和PLR将患者分为3个预后组：高危组（血小板增多症伴任何PLR）；中危组（PLR升高但无血小板增多症）；低危组（以上均无），这使得能够进行个体化且准确的生存估计。
确定宫颈癌患者的基线特征和临床结局。根据患者治疗前的血小板计数或PLR进行分组，然后比较这些组之间的临床病理特征和患者生存情况。使用时间依赖性接受者操作特征（ROC）分析比较血小板计数和PLR的临床效用。
治疗前血小板增多症和升高的PLR被确定为宫颈癌患者的独立预测因素。血小板计数在预测子宫颈癌患者预后方面优于PLR。我们由血小板计数和PLR组成的预后模型提供个体化的生存估计。
